Company’s New Groundbreaking Preclinical Data in NSCLC Models Provides Further Validation for SIL204's Innovative Delivery ...

Revolution Medicines Inc. (NASDAQ:RVMD) is one of the most promising stocks according to Wall Street analysts. On June 23, ...

Recent developments in protein-protein interactions (PPI) give hope for patients with advanced or untreatable diseases.

Amgen has transitioned into a mature, cash-generating pharma-biotech hybrid. Click here to find out why AMGN stock is a Buy.

In combination with a KRAS inhibitor, HotSpot’s CBM signalosome inhibitor achieved complete suppression of downstream signalling in KRASG12X cell lines. HotSpot’s CBM signalosome inhibitor ...

Fintel reports that on July 8, 2025, Ladenburg Thalmann initiated coverage of Cardiff Oncology (NasdaqCM:CRDF) with a Buy recommendation. Analyst Price Forecast Suggests 272.32% Upside As of June 20, ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

John Houston, Ph.D., Chairperson, CEO and President at Arvinas, Announces Plans to Retire as CEO Upon Appointment of ...

Podravka and Kraš have come together across the pond on the US market to strengthen the image of Croatia's products abroad.

A new drug targets RAS-PI3Kα pathways without harmful side effects. It was developed using high-performance computing and AI.